Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Date:4/23/2009

n the recently completed Phase Ib clinical trial of ANA598 in HCV patients in a late-breaker poster entitled, "Antiviral Activity of ANA598, a Potent Non-Nucleoside Polymerase Inhibitor, In Chronic Hepatitis C Patients," at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL). In the Phase Ib study, ANA598 treatment resulted in rapid and sustained reductions in HCV RNA with median reductions at end of treatment (Day 4) exceeding 2 log10 (>99%) at all dose levels. At 200 mg bid, the median viral load reduction was 2.4 log10 (range of 0.4 to 3.4); at 400 mg bid, 2.3 log10 (range of 1.6 to 3.5); and at 800 mg bid, 2.9 log10 (range of 2.2 to 3.4). Genotype 1a patients demonstrated median reductions of 1.4 log10, 1.8 log10, and 2.5 log10 at 200, 400 and 800 mg bid, respectively. In 10 of the 12 genotype 1a patients who received ANA598, viral load was still declining at the end of the three days of treatment. Genotype 1b patients demonstrated median reductions of 2.6 log10, 2.5 log10 and 3.2 log10, at 200, 400 and 800 mg bid, respectively. No patient showed evidence of viral rebound while on ANA598. ANA598 was well-tolerated in this short term study and there were no serious adverse events.

  • 14-day Healthy Volunteer Study. Anadys recently completed dosing healthy volunteers in a 14-day study conducted to extend the safety and pharmacokinetic profile of ANA598. Thirty subjects participated in the study, with eight subjects receiving ANA598 and two subjects receiving placebo at each dose level (400 mg once-daily, 800 mg once-daily and 600 mg bid). Subjects received a single dose on day one followed by pharmacokinetic assessment over days two and three and received subsequent doses consecutively on days four through fourteen. Preliminary results from the study indicate that ANA598 was generally well-tolerated in all cohorts with no serious adverse events, al
    '/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... DUBLIN , September 19, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the ... Pre-packed Chromatography Columns"  report to their offering.  ... columns market is one of the fastest-growing segments ... at $1.2 billion in 2013, and expected to ...
(Date:9/18/2014)... 2014 HealthTronics, Inc ., ... radiology products and services, announced that a poster ... cryoablation) versus external beam radiotherapy (EBRT) is being ... Urological Association (MAAUA) Annual Meeting in Baltimore, Maryland ... of Cryosurgery and External Beam Radiation as Treatments ...
(Date:9/18/2014)... Mich. , Sept. 18, 2014  Health Enhancement Products, ... firm investigating early-stage algae bioactive compounds and metabolic processes, is ... the company,s board of directors. Ms. Nola E. Masterson ... investment advisor joined the board effective September 17, 2014. ... Masterson agree to join our board," states Andrew Dahl ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global and Chinese Stem Cell Industry Report, 2014-2017" ... cells are undifferentiated biological cells that can differentiate into ... more stem cells. Stem cell therapy can be applied ... hematological system disease), nervous system diseases, damage or lesion ...
Breaking Biology Technology:Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3
... Getty Images The Olympics of Biotech , ,The ... year. Though this is still a primarily American-influenced event, it ... the industry becomes part of the economies of many countries. ... two weeks, the biotech Olympics run about four days every ...
... the market began its downward trend three years ago ... the financial strain. However, as the price of computers ... the need for IT services grew. Many IT staffers ... their IT staff before, and looked to begin working ...
... - A free online collection of multimedia resources on children's ... books and authors has launched on a Wisconsin ... the school year. , , TeachingBooks is a new ... journal and newspaper articles, encyclopedias and other resources to Wisconsin ...
Cached Biology Technology:The Olympics: A Biotech Perspective 2The Olympics: A Biotech Perspective 3Expetec expands IT staff services in Wisconsin 2Expetec expands IT staff services in Wisconsin 3TeachingBooks brings free K-12 resources to Wisconsin residents 2
(Date:9/18/2014)... Wis. No matter how many times it,s ... social, communicating creatures. , But by using ... organisms radically alter their behavior to suit their ... of them are present, and act accordingly. , ... millions, it may change from innocuous to pathogenic, ...
(Date:9/18/2014)... manipulate spoken language is unique to humans. "The genetic ... of human evolution to make this possible are largely ... now have," says Wolfgang Enard, Professor of Anthropology and ... the molecular biological basis of language Enard has now ... latest study, undertaken in collaboration with scientists at several ...
(Date:9/18/2014)... researchers and their colleagues have built the first ... academic performance and behavioral trends. In other words, ... even if you don,t -- and how that ... students, happiness, stress, depression and loneliness to their ... general population for example, to monitor mental ...
Breaking Biology News(10 mins):Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4
... A Webinar hosted by TorreyPines Therapeutics, Inc. (NASDAQ: ... bring together industry experts to discuss the opportunity ... the inhibition of the neurotransmitter glutamate. The company,s ... moderate a discussion following brief presentations by: ...
... (June 20, 2008) The future of high-intensity x-ray ... U.S. Department of Energy,s Argonne National Laboratory have devised ... "The free electron laser oscillator (X-FELO) we are proposing ... brighter than currently operating machines," Argonne Distinguished fellow Kwang-Je ...
... knowfor sure. Adding to a growing literature ,on ... ,function, it is now shown that one lactate dehydrogenase family ... ,work on this glycolytic enzyme had shown that it is ... ,only speculative. In an article on p. 26 Odet et ...
Cached Biology News:Treating chronic pain, migraine & muscle spasticity through inhibition of neurotransmitter glutamate 2Treating chronic pain, migraine & muscle spasticity through inhibition of neurotransmitter glutamate 3A novel X-ray source could be brightest in the world 2July 2008 highlights 2
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
MW5...
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
... the membrane-permeant ester forms (CCF2-AM and ... beta-lactamase substrates, CCF2 and CCF4. These ... where cleavage by endogeneous cytoplasmic esterases ... charged forms, thereby trapping them in ...
Biology Products: